| 38.835 0.905 (2.39%) | 08-19 10:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 45.61 |
1-year : | 53.27 |
| Resists | First : | 39.04 |
Second : | 45.61 |
| Pivot price | 36.6 |
|||
| Supports | First : | 35.93 |
Second : | 34 |
| MAs | MA(5) : | 37.17 |
MA(20) : | 36.46 |
| MA(100) : | 32.76 |
MA(250) : | 31.91 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 83 |
D(3) : | 72.6 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 40.58 | Low : | 23.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IDYA ] has closed Bollinger Bands are 36.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.01 - 38.16 | 38.16 - 38.32 |
| Low: | 36 - 36.15 | 36.15 - 36.33 |
| Close: | 37.63 - 37.89 | 37.89 - 38.18 |
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Wed, 19 Aug 2026
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
Sun, 16 Aug 2026
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Sat, 15 Aug 2026
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Sat, 15 Aug 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Sat, 15 Aug 2026
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Fri, 14 Aug 2026
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 9.564e+007 (%) |
| Held by Institutions | 2.1 (%) |
| Shares Short | 10,630 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.142e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -74.8 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 380.7 % |
| Return on Equity (ttm) | -11.6 % |
| Qtrly Rev. Growth | 2.3413e+008 % |
| Gross Profit (p.s.) | -1.1 |
| Sales Per Share | 2.48 |
| EBITDA (p.s.) | -1.79 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 15.43 |
| Price to Cash Flow | -0.33 |
| Dividend | 0 |
| Forward Dividend | 9.57e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|